Endotypes of Chronic Rhinosinusitis; relationships to disease phenotypes, pathogenesis, clinical findings and treatment approaches.
Short Title: Relating endotypes, phenotypes and treatments in CRS
Atsushi Kato*, PhD1, Anju T. Peters*, MD, MSCI1,2, Whitney W. Stevens, MD, PhD1,2, Robert P. Schleimer***, PhD1,2, Bruce K. Tan**, MD, MS1,2, Robert C. Kern**, MD2
*,** These authors contributed equally
*** Correspondence
1 Division of Allergy and Immunology, Department of Medicine and 2Department of Otolaryngology – Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Conflicts of Interest: AK reports a consultant fee from Astellas Pharma and a gift for his research from Lyra Therapeutics. AP has served on advisory boards for Sanofi-Genzyme/Regeneron, Optinose, AstraZeneca, Novartis, and GSK. WWS served on advisory boards for GlaxoSmithKline, Genentech, and Bristol Myers Squibb and on a speaker’s bureau for GlaxoSmithKline. RPS reports consulting fees from Intersect ENT, Merck, GlaxoSmithKline, Sanofi, AstraZeneca/Medimmune, Genentech, Actobio Therapeutics, Lyra Therapeutics, Astellas Pharma, Allakos and Otsuka. RPS also receives royalties from Siglec-8 and Siglec-8 ligand related patents licensed by Johns Hopkins to Allakos Inc. BKT served on advisory boards for Sanofi-Genzyme/Regeneron. RCK is a consultant for Lyra Therapeutics.
Keywords: Chronic Rhinosinusitis, Endotype, Inflammation, Nasal polyps, Phenotype
Word Count: 5,067
Address correspondence to Robert Schleimer, PhD
The Roy and Elaine Patterson Professor
Chief, Allergy and Immunology
Northwestern University Feinberg School of Medicine
240 E. Huron St., Room M-318
Chicago, IL 60611 USA
312-503-0076
rpschleimer@northwestern.edu